New therapy for Periventricular leucomalacia using mesenchymal stem cell

2014 Fiscal Year Final Research Report

• Project/Area Number: 24659507
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: TAKI Atsuko 東京医科歯科大学, 医学部附属病院, 助教 (20614481)
• Co-Investigator(Renkei-kenkyūsha): KOMAKI Motohiro 東京医科歯科大学, 歯学部付属病院, 准教授 (30401368) ; IWASAKI Kengo 東京医科歯科大学, 歯学部付属病院, 講師 (40401351)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 子宮内感染 / 脳室周囲白質軟化症 / 間葉系幹細胞 / 再生治療

Outline of Final Research Achievements

In this study we explore the therapeutic effects of MSC or MSC-conditioned medium (MSC-CM) on LPS-induced rat PVL model. Umbilical cord-derived MSC (UCMSC, Lonza) were purchased. Four-day old rats were intraperitoneally challenged with LPS to create PVL model and simultaneously treated by culture medium (control), MSC, or MSC-CM. Immuno-staining of myelin basic protein (MBP) in brain sections was used to evaluate cerebral white matter. Real time-PCR was performed to quantitate proinflammatory cytokine levels in 6-day-old rat brain.Postnatal LPS challenge caused PVL in rats, evaluated by increased inflammatory chytokines on day 6, and loss of MBP on day 12. Both MAS and MSC-CM significantly attenuated the cytokine level whereas only MSC attenuated loss of MBP.Our results showed that therapeutic potential of MSC due to anti-inflammatory effects in rat PVL model. The differences between MSC and MSC-CM suggests direct cellular effects are necessary for preventing MBP loss in PVL.

Free Research Field

発生発達病態学